120 related articles for article (PubMed ID: 29100358)
1. Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide.
Øverbye A; Holsæter AM; Markus F; Škalko-Basnet N; Iversen TG; Torgersen ML; Sønstevold T; Engebraaten O; Flatmark K; Mælandsmo GM; Skotland T; Sandvig K
Oncotarget; 2017 Sep; 8(44):76921-76934. PubMed ID: 29100358
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
Fonseca NA; Gomes-da-Silva LC; Moura V; Simões S; Moreira JN
J Control Release; 2014 Dec; 196():122-31. PubMed ID: 25305563
[TBL] [Abstract][Full Text] [Related]
4. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.
Stover TC; Sharma A; Robertson GP; Kester M
Clin Cancer Res; 2005 May; 11(9):3465-74. PubMed ID: 15867249
[TBL] [Abstract][Full Text] [Related]
5. Liposomal short-chain C6 ceramide induces potent anti-osteosarcoma activity in vitro and in vivo.
Zhai L; Sun N; Han Z; Jin HC; Zhang B
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):274-80. PubMed ID: 26505795
[TBL] [Abstract][Full Text] [Related]
6. C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth.
Flowers M; Fabriás G; Delgado A; Casas J; Abad JL; Cabot MC
Breast Cancer Res Treat; 2012 Jun; 133(2):447-58. PubMed ID: 21935601
[TBL] [Abstract][Full Text] [Related]
7. Targeted liposomal doxorubicin/ceramides combinations: The importance to assess the nature of drug interaction beyond bulk tumor cells.
Cruz AF; Fonseca NA; Malheiro AR; B Melo J; Gaspar MM; Fernandes R; Moura V; Simões S; Moreira JN
Eur J Pharm Biopharm; 2022 Mar; 172():61-77. PubMed ID: 35104605
[TBL] [Abstract][Full Text] [Related]
8. Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro.
Shabbits JA; Mayer LD
Biochim Biophys Acta; 2003 May; 1612(1):98-106. PubMed ID: 12729935
[TBL] [Abstract][Full Text] [Related]
9. Effect of ceramide N-acyl chain and polar headgroup structure on the properties of ordered lipid domains (lipid rafts).
Megha ; Sawatzki P; Kolter T; Bittman R; London E
Biochim Biophys Acta; 2007 Sep; 1768(9):2205-12. PubMed ID: 17574203
[TBL] [Abstract][Full Text] [Related]
10. Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells.
Stover T; Kester M
J Pharmacol Exp Ther; 2003 Nov; 307(2):468-75. PubMed ID: 12975495
[TBL] [Abstract][Full Text] [Related]
11. Rapid distribution of liposomal short-chain ceramide in vitro and in vivo.
Zolnik BS; Stern ST; Kaiser JM; Heakal Y; Clogston JD; Kester M; McNeil SE
Drug Metab Dispos; 2008 Aug; 36(8):1709-15. PubMed ID: 18490436
[TBL] [Abstract][Full Text] [Related]
12. Liposomal C6 Ceramide Activates Protein Phosphatase 1 to Inhibit Melanoma Cells.
Jiang F; Jin K; Huang S; Bao Q; Shao Z; Hu X; Ye J
PLoS One; 2016; 11(9):e0159849. PubMed ID: 27631768
[TBL] [Abstract][Full Text] [Related]
13. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.
Shroff K; Kokkoli E
Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611
[TBL] [Abstract][Full Text] [Related]
14. Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition.
Ji C; Yang B; Yang YL; He SH; Miao DS; He L; Bi ZG
Oncogene; 2010 Dec; 29(50):6557-68. PubMed ID: 20802518
[TBL] [Abstract][Full Text] [Related]
15. Systemic Codelivery of a Homoserine Derived Ceramide Analogue and Curcumin to Tumor Vasculature Inhibits Mouse Tumor Growth.
Barui S; Saha S; Yakati V; Chaudhuri A
Mol Pharm; 2016 Feb; 13(2):404-19. PubMed ID: 26716471
[TBL] [Abstract][Full Text] [Related]
16. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
17. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
Charrois GJ; Allen TM
Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
[TBL] [Abstract][Full Text] [Related]
18. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
[TBL] [Abstract][Full Text] [Related]
19. Short-chain C6 ceramide sensitizes AT406-induced anti-pancreatic cancer cell activity.
Zhao X; Sun B; Zhang J; Zhang R; Zhang Q
Biochem Biophys Res Commun; 2016 Oct; 479(2):166-172. PubMed ID: 27562715
[TBL] [Abstract][Full Text] [Related]
20. The Enhanced Efficacy of Intracellular Delivery of Doxorubicin/C6-Ceramide Combination Mediated by the F3 Peptide/Nucleolin System Is Supported by the Downregulation of the PI3K/Akt Pathway.
Cruz AF; Caleiras MB; Fonseca NA; Gonçalves N; Mendes VM; Sampaio SF; Moura V; Melo JB; Almeida RD; Manadas B; Simões S; Moreira JN
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
